FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study. PMID 40100121 · Clin Cancer Res · 2025-Jun-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Cytarabine Pharmacogenomics and Outcomes Among Children and Young Adults With Acute Myeloid Leukemia. PMID 40549387 · JAMA Netw Open · 2025-Jun-02 The record describes a pharmacogenomic cohort study analyzing outcomes from a randomized trial (AAML1031) and other protocols. While it contains elements of a randomized trial (AAML1031) with drug intervention and time-to-event endpoints, the abstract does not explicitly state the phase of the AAML1031 trial (Phase II, III, etc.), and the primary analysis is a retrospective pharmacogenomic validation study across multiple cohorts, not a primary report of the definitive randomized trial efficacy results. Therefore, eligibility cannot be definitively established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Interaction effect of comorbid depression and proactive positivity coping strategy on the 1-year survival of patients with advanced cancer: a nationwide multicentre study in South Korea. PMID 40457290 · BMC Psychiatry · 2025-Jun-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A home-based 12-week chair exercise intervention for older adults with advanced cancer receiving chemotherapy: a randomized pilot feasibility trial. PMID 40455316 · Support Care Cancer · 2025-Jun-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| HPV genotyping agreement between paired cervical cytological sample and biopsy across lesion severity and vaccination. PMID 40452051 · Virol J · 2025-Jun-02 The record describes a diagnostic agreement study from an ancillary analysis within a randomized trial. It lacks a therapeutic drug intervention and does not report a time-to-event efficacy endpoint (OS, PFS, etc.) as the primary/key secondary outcome. The phase and randomization are noted, but the core study question is not eligible per the cohort definition. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized Phase II Clinical Trial of Sulforaphane in Former Smokers at High Risk for Lung Cancer. PMID 40041932 · Cancer Prev Res (Phila) · 2025-Jun-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Synergistic effects of PD-1 antibody and chemotherapy followed by surgery-centric local treatment in patients with limited-metastatic gastric or gastroesophageal adenocarcinoma (ROSETTE trial): an open-label, single-center, randomized phase 2 trial. PMID 40452026 · BMC Cancer · 2025-Jun-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of a community health advisor colorectal cancer screening educational intervention on stool test completion in an African American primary care patient population: a pragmatic randomized controlled trial. PMID 40450376 · BMC Glob Public Health · 2025-Jun-01 Study is a randomized controlled trial in oncology (colorectal cancer screening) with human subjects and reports primary results. However, it is excluded because: 1) The intervention is a non-drug educational/community health advisor program, not a drug-containing intervention. 2) The primary efficacy endpoint is the proportion completing stool test at 12 months (a binary outcome), not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, TTP, nor are Kaplan-Meier curves or hazard ratios reported. The trial registration number is provided but no phase is explicitly stated. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized controlled trial reporting guidelines should be updated to include information on subsequent treatments. PMID 40440214 · Cancer · 2025-Jun-01 The record is an editorial/commentary advocating for updated reporting guidelines, not an original report of a randomized trial with results. It discusses oncology trials and time-to-event endpoints (e.g., PFS2) but does not present primary or secondary efficacy data from a specific Phase III or definitive trial. It lacks explicit human trial phase information and drug intervention details for a specific study. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Characterization of Belantamab Mafodotin-Induced Corneal Changes in Patients With Multiple Myeloma. PMID 40338596 · JAMA Ophthalmol · 2025-Jun-01 The record describes a phase 3b case series study characterizing ocular side effects of belantamab mafodotin in multiple myeloma patients. While it is an oncology study with a drug intervention in humans and phase 3/3b, it is non-randomized and its primary endpoint is pathologic characterization of corneal changes, not a time-to-event efficacy outcome. Therefore, it does not meet the eligibility criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer: A Randomized Clinical Trial. PMID 40244574 · JAMA Oncol · 2025-Jun-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| VERY EARLY USE OF ESMOLOL IN HYPERKINETIC SEPTIC SHOCK PATIENTS WITH PERSISTENT TACHYCARDIA: A RANDOMIZED CONTROLLED PILOT STUDY. PMID 40101954 · Shock · 2025-Jun-01 The record describes a randomized controlled pilot study in septic shock (non-oncology) evaluating esmolol for heart rate control. It is not a trial of human malignant neoplasm, does not report a Phase III/IIIb or Phase II/III trial, and its primary efficacy endpoint is not a time-to-event outcome (e.g., OS, PFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Nasal biomarker inflammatory profile in response to intranasal corticosteroids in pediatric obstructive sleep apnea syndrome. PMID 40051199 · J Clin Sleep Med · 2025-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Abatacept and the risk of malignancy: a meta-analysis across disease indications. PMID 39992258 · Rheumatology (Oxford) · 2025-Jun-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Concurrent and Consolidative Carboplatin Plus Nab-Paclitaxel or Paclitaxel in Locally Advanced NSCLC: A Multicenter, Randomized Clinical Trial. PMID 39922319 · Int J Radiat Oncol Biol Phys · 2025-Jun-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomized Evaluation of the PET-Adjusted IMRT for NSCLC Trial (REPAINT). PMID 39862898 · Int J Radiat Oncol Biol Phys · 2025-Jun-01 The trial compares radiation therapy techniques (standard vs. dose-painted RT), not a drug intervention. While concurrent chemotherapy is given in both arms, it is standard background therapy, not the tested drug intervention. The phase is not explicitly stated as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Quantitative benefit-risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinoma. PMID 41646284 · ESMO Gastrointest Oncol · 2025-Jun The record describes a secondary benefit-risk assessment analysis of a Phase III randomized trial, not a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Clinical study on the effect of glycosaminoglycans on vascular endothelial glycocalyx in sepsis]. PMID 40820527 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2025-Jun The study is a randomized trial in sepsis patients, which is not an oncology indication. While it involves a drug intervention (glycosaminoglycans), it does not assess a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) in human malignant neoplasms. It measures biomarker levels, clinical scores, and short-term mortality, not Kaplan-Meier or hazard ratio data for cancer outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The efficacy of mosapride on recovery of intestinal motility after elective colorectal cancer surgery: a randomized controlled trial. PMID 40598989 · Ann Coloproctol · 2025-Jun Study is an oncology RCT with a drug intervention and reports primary results, but its primary efficacy endpoints (time to first bowel movement, time to flatus) are not time-to-event endpoints in the required sense (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Primary Cytoreductive Surgery Versus Neoadjuvant Chemotherapy Followed by Surgery in Patients with Advanced Primary Epithelial Ovarian Cancer in Low Resources Setting: A Randomized Clinical Trial. PMID 40584804 · J Obstet Gynaecol India · 2025-Jun The study is a randomized, oncology, human trial with drug intervention and time-to-event endpoints. However, the trial phase is not explicitly stated in the abstract or metadata as Phase III/IIIb or Phase II/III. The 'METHOD' section mentions a randomized controlled trial but does not specify the phase. The deterministic review flagged 'phase3_evidence_unclear'. Without explicit phase information meeting the inclusion criteria, the record is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Demographics and Immunotherapy Efficacy for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Phase III Clinical Trials. PMID 40547956 · Liver Cancer · 2025-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Early intensive blood pressure management after endovascular treatment in ischaemic stroke (IDENTIFY): a multicentre, open-label, blinded-endpoint, randomised controlled trial. PMID 40538518 · Lancet Reg Health West Pac · 2025-Jun The study is a randomised controlled trial in acute ischaemic stroke (non-oncology), with a primary endpoint of functional outcome at 90 days (not a time-to-event efficacy endpoint like OS, PFS, etc.). It evaluates intensive blood pressure management (a physiological intervention), not a drug-containing intervention. Therefore, it does not meet multiple core eligibility criteria for the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Randomized Trial of Nutrition and Exercise Treatment in Patients With Pancreatic and Non-Small Cell Lung Cancer (NEXTAC-TWO). PMID 40522817 · J Cachexia Sarcopenia Muscle · 2025-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies. PMID 40515823 · Ann Hematol · 2025-Jun The study is a Phase III randomized trial of crovalimab in paroxysmal nocturnal hemoglobinuria (PNH). PNH is not classified as a human malignant neoplasm (cancer). Furthermore, the primary endpoint is patient-reported outcomes (PROs) related to quality of life and fatigue, not a time-to-event efficacy endpoint such as OS, PFS, or DFS. Therefore, it does not meet the oncology cohort eligibility criteria. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Sample Size Assessment and Interim Analysis Strategies for Survival Trial Designs With Covariate-Adaptive Randomization. PMID 40481756 · Stat Med · 2025-Jun The record is a methodological study on sample size and interim analysis strategies for survival trials, not a report of a clinical trial's efficacy results. While it mentions oncology (lung neoplasms) and uses survival analysis concepts, it does not present original results from a randomized trial with a drug intervention and a primary time-to-event efficacy endpoint. It lacks explicit mention of a Phase III or definitive Phase II/III design, a drug-containing intervention arm, and a primary time-to-event endpoint like OS or PFS with Kaplan-Meier or HR data. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial. PMID 40472658 · ESMO Open · 2025-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer. PMID 40461366 · Gynecol Oncol · 2025-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study. PMID 40449497 · Lancet Oncol · 2025-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomized Study of Short-time Continuous Saline Irrigation After Transurethral Resection in Non-muscle Invasive Bladder Cancer. PMID 40425326 · Anticancer Res · 2025-Jun The study is a randomized trial with a time-to-event endpoint (RFS) in oncology, but the intervention does not involve a drug; it compares two durations of a non-drug procedure (saline irrigation). Therefore, it does not meet the criterion for a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| COREGO: drug-drug interaction analysis on the efficacy and safety of regorafenib in patients with a sarcoma: pooled analysis of the data from the REGOSARC and REGOBONE trials. PMID 40412007 · ESMO Open · 2025-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A treatment-related death predictive score for treatment-naïve advanced non-small cell lung cancer. PMID 40409025 · Lung Cancer · 2025-Jun The record is an oncology RCT involving drug interventions and reports a time-to-event endpoint (OS hazard ratio). However, the study phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided text, and the primary focus is on developing a predictive score for treatment-related deaths, which constitutes a secondary or subgroup analysis rather than reporting the primary trial efficacy results. Therefore, eligibility cannot be fully established without confirmation of phase and primary trial report status. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer. PMID 40408921 · ESMO Open · 2025-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| High acupuncture expectancy is associated with shorter time to ovulation and higher chances of ovulation in infertile patients with PCOS receiving acupuncture: a secondary analysis of a randomized controlled trial. PMID 40390321 · Acupunct Med · 2025-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-study. PMID 40379410 · Radiother Oncol · 2025-Jun The study is a randomized Phase III trial in oncology reporting original results, but it lacks a drug-containing intervention (it compares radiotherapy fractionation schedules) and does not have a primary or key secondary time-to-event efficacy endpoint (the primary endpoint is patient-reported arm/hand swelling, a toxicity/safety outcome). Therefore, it does not meet all eligibility criteria. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Concurrent chemotherapy for older patients with locoregionally advanced nasopharyngeal carcinoma: A randomized clinical trial. PMID 40378722 · J Geriatr Oncol · 2025-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre randomised controlled trial. PMID 40347959 · Lancet Gastroenterol Hepatol · 2025-Jun 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Midazolam with fentanyl for endobronchial ultrasound-guided transbronchial needle aspiration: a randomized, double-blind, phase III study. PMID 40345066 · Lung Cancer · 2025-Jun The study is an oncology-related, human, randomized Phase III trial with original results. However, it does not meet the required primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR analysis). The primary endpoint is a composite sedation/procedural success outcome, not a time-to-event efficacy outcome. Furthermore, while fentanyl and midazolam are drugs, the intervention is for sedation support during a diagnostic procedure, not a therapeutic anticancer drug intervention. The record's deterministic review correctly identified the lack of time-to-event signal. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Plain language summary of MARIPOSA-2: amivantamab-chemotherapy either with or without lazertinib for treatment of non-small-cell lung cancer. PMID 40326044 · Future Oncol · 2025-Jun The record is a plain language summary, not an original formal-result report. The empty abstract and lack of specific trial details (phase, randomization, endpoints) in the metadata prevent establishment of required eligibility criteria. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Esophagus-sparing radiotherapy for complicated spinal metastases (ESO-SPARE). A randomized phase III clinical trial. PMID 40324910 · Radiother Oncol · 2025-Jun The trial is a randomized phase III oncology study with original results, but it is excluded because it lacks a drug-containing intervention (it compares radiotherapy techniques) and does not have a time-to-event efficacy endpoint; its primary endpoints are patient-reported symptom and function outcomes at fixed time points. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Indirect Comparisons of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with R/R MCL: An Extended Follow-up Analysis. PMID 40317419 · Adv Ther · 2025-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Oncologic outcomes of minimally invasive surgery vs. abdominal hysterectomy in patients with low-risk, early-stage cervical cancer: A retrospective analysis of KGOG 1028 data based on SHAPE trial eligibility criteria. PMID 40311526 · Gynecol Oncol · 2025-Jun The study is a retrospective analysis of a prior cohort (KGOG 1028) comparing surgical approaches (MIS vs. abdominal hysterectomy). It is not a randomized trial, is not a Phase III or II/III trial, and does not involve a drug intervention. Therefore, it does not meet the eligibility criteria for inclusion in the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial. PMID 40300425 · Gynecol Oncol · 2025-Jun The study is an original, Phase IIIb, single-arm trial of a drug (olaparib) in human oncology with a primary/key secondary time-to-event efficacy endpoint (overall survival). However, the record explicitly states it is 'single-arm' and 'non-comparator', which does not meet the requirement for a randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Maintenance Therapy With Adjuvant Chemotherapy of Three Steps in Patients Newly Diagnosed With Advanced Ovarian Cancer: A Phase II Randomised Clinical Trial. PMID 40292604 · BJOG · 2025-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Anticancer effects of vitamin K combined with transarterial chemoembolization in hepatocellular carcinoma, a randomized controlled trial. PMID 40263401 · Br J Cancer · 2025-Jun 命中用户提供的消化道肿瘤阳性参考集。 |
B
|
影子组漏检补回 | eligiblepositive_reference | confirmed 1 Figure · 2 Panel · risk visible |
| Safety and efficacy of combined portal and hepatic vein embolisation in patients with colorectal liver metastases (DRAGON1): a multicentre, single-arm clinical trial. PMID 40255933 · Lancet Reg Health Eur · 2025-Jun The study is a single-arm, multicenter trial evaluating the safety and efficacy of a procedural intervention (PVE/HVE) for colorectal liver metastases. It is not randomized, not a drug intervention, and does not report a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet the eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B). PMID 40248173 · Contemp Clin Trials Commun · 2025-Jun 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Vitamin D Supplementation During Neoadjuvant Chemotherapy for Breast Cancer Improves Pathological Complete Response: A Prospective Randomized Clinical Trial. PMID 40229998 · World J Surg · 2025-Jun The study is a randomized oncology trial with a drug intervention and reports original results. However, the primary endpoint is pCR (a pathological response rate), not a time-to-event endpoint like OS or PFS. Therefore, it does not meet the required time-to-event efficacy endpoint criterion for this cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of intravenous vedolizumab treatment in Chinese patients with moderate-to-severe Crohn's disease. PMID 40228712 · Clin Res Hepatol Gastroenterol · 2025-Jun The study is a well-conducted Phase III randomized trial with a drug intervention, but it is not oncology and does not have a time-to-event efficacy endpoint as required. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial. PMID 40228513 · Lancet Gastroenterol Hepatol · 2025-Jun The trial is not oncology-focused (ulcerative colitis), the primary endpoint is a binary relapse rate, not a time-to-event endpoint, and the phase is not explicitly stated as definitive (Phase III/IIIb). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Mepitel Film Versus StrataXRT in Managing Radiation Dermatitis in an Intra-Patient Controlled Clinical Trial of 80 Postmastectomy Patients. PMID 40223795 · J Med Imaging Radiat Oncol · 2025-Jun The trial is a Phase III randomized controlled trial in human breast cancer patients, but the intervention (Mepitel film) is a device, not a drug, and the primary endpoint (moist desquamation) is a categorical incidence outcome, not a time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it does not meet the inclusion criteria for drug-intervention or time-to-event endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |